Skip to main content
Genmab logo

Genmab — Investor Relations & Filings

Ticker · GMAB ISIN · DK0010272202 LEI · 529900MTJPDPE4MHJ122 CO Manufacturing
Open in API
Filings indexed 2,819 across all filing types
Latest filing 2021-11-04 Foreign Filer Report
Country DK Denmark
Listing CO GMAB

About Genmab

https://www.genmab.com/

Genmab is an international biotechnology company that specializes in the creation, development, and commercialization of differentiated antibody therapeutics. The company focuses on transforming the treatment of cancer and other serious diseases. By utilizing proprietary antibody technology platforms and scientific expertise, Genmab develops a pipeline of innovative medicines. Its activities span from discovery and research through clinical development to deliver novel therapies to patients.

Recent filings

Filing Released Lang Actions
6-K
Foreign Filer Report
2021-11-04 English
Genmab Improves its 2021 Financial Guidance
Earnings Release Classification · 95% confidence The document is a company announcement from Genmab regarding an update to its 2021 financial guidance. It provides revised revenue and operating expense projections. While it contains financial data, it is an initial announcement of updated expectations rather than a full quarterly or annual report. According to the 'Menu vs Meal' rule, this is a short announcement (under 5,000 characters of core content) that serves as a press release/announcement of financial guidance, which fits the 'Earnings Release' (ER) category as it provides key financial highlights and guidance updates. FY 2021
2021-11-04 English
Earnings Release 2021
Earnings Release Classification · 100% confidence The document is titled "Genmab Improves its 2021 Financial Guidance" and is explicitly labeled as a "Company Announcement." It provides updated financial projections (Revenue, Operating expenses, Operating result) for the full year 2021, driven by royalty revenue estimates. This is a preliminary announcement of updated financial performance expectations, not the full, comprehensive report (like a 10-K or IR). It is also not a transcript (CT), a formal audit report (AR), or a detailed investor presentation (IP). The content aligns best with an Earnings Release (ER), which covers initial announcements of periodical financial results and key highlights, even though this specific announcement is an *update* to guidance rather than the initial release for the period. The document also mentions that the full results for the first nine months will be published later, confirming this is a summary/guidance update, fitting the ER definition. FY 2021
2021-11-04 English
6-K
Foreign Filer Report
2021-10-19 English
Genmab Announces Net Sales of DARZALEX® (daratumumab) for the Third Quarter of 2021
Earnings Release Classification · 95% confidence The document is a 'Company Announcement' from Genmab regarding the net sales of a specific product (DARZALEX) for the third quarter of 2021. It provides key financial highlights (sales figures) rather than a full quarterly report. According to the filing definitions, an initial announcement of quarterly financial results (key highlights only) is classified as an Earnings Release (ER). Q3 2021
2021-10-19 English
Earnings Release 2021
Earnings Release Classification · 100% confidence The document is titled "Genmab Announces Net Sales of DARZALEX® (daratumumab) for the Third Quarter of 2021" and provides specific financial figures (USD 1,580 million in net sales) for a defined period (Q3 2021). This content structure—announcing key financial results for a specific reporting period—is characteristic of an Earnings Release (ER). Although it mentions the full Annual Report on Form 20-F in the forward-looking statements disclaimer, the primary purpose of this specific document is the immediate announcement of quarterly sales figures, not the comprehensive annual filing itself. It is not a full transcript (CT), a comprehensive interim report (IR), or a general regulatory filing (RNS), but a targeted financial results announcement. Q3 2021
2021-10-19 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.